Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

1.850 -0.160 (-7.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,199,853
Open 2.090
Bid (Size) 1.840 (300)
Ask (Size) 1.870 (600)
Prev. Close 2.010
Today's Range 1.840 - 2.210
52wk Range 1.070 - 11.46
Shares Outstanding 57,943,066
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
Unusual volume stocks in Monday's session ↗
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill

Performance

YTD
-64.1%
-64.1%
1 Month
-81.9%
-81.9%
3 Month
-76.0%
-76.0%
6 Month
-54.5%
-54.5%
1 Year
-58.3%
-58.3%

More News

Read More
News headline image
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
From Hagens Berman
Via Business Wire
News headline image
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
From DJS Law Group
Via Business Wire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
RZLT Stock Lost Nearly 90% Of Its Value Today – What Did The Company’s Latest Trial Reveal? ↗
Via Stocktwits
News headline image
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
Rezolute Inc (NASDAQ:RZLT) Reports Q4 FY2025 Results, Posts Wider-Than-Expected Loss Amid Strong Clinical Progress ↗
Via Chartmill
News headline image
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout ↗
Via MarketBeat
News headline image
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
From Rezolute, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rezolute, Inc. - Common Stock (NV) publicly traded?
Yes, Rezolute, Inc. - Common Stock (NV) is publicly traded.
What exchange does Rezolute, Inc. - Common Stock (NV) trade on?
Rezolute, Inc. - Common Stock (NV) trades on the Nasdaq Stock Market
What is the ticker symbol for Rezolute, Inc. - Common Stock (NV)?
The ticker symbol for Rezolute, Inc. - Common Stock (NV) is RZLT on the Nasdaq Stock Market
What is the current price of Rezolute, Inc. - Common Stock (NV)?
The current price of Rezolute, Inc. - Common Stock (NV) is 1.850
When was Rezolute, Inc. - Common Stock (NV) last traded?
The last trade of Rezolute, Inc. - Common Stock (NV) was at 12/18/25 04:00 PM ET
What is the market capitalization of Rezolute, Inc. - Common Stock (NV)?
The market capitalization of Rezolute, Inc. - Common Stock (NV) is 107.19M
How many shares of Rezolute, Inc. - Common Stock (NV) are outstanding?
Rezolute, Inc. - Common Stock (NV) has 107M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.